Eli Lilly presents cancer data: Eli Lilly stock trades 2.68 percent below its high

Published on 10/26/2026 at 11:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue was USD 22.97 billion, up 47.7 percent year on year. Eli Lilly stock costs EUR 1,144.30 on October 26, 2026, 0.03 percent below Xetra close.

Clinical pipeline and earnings calendar

Clinical data from October 24, 2026 added a new oncology milestone for Eli Lilly.
Second-quarter revenue reached USD 22.97 billion, up 47.70 percent year on year.
Eli Lilly stock trades at EUR 1,144.30 at 11:30 a.m. CET at Lang & Schwarz on October 26, 2026, 0.03 percent below the Xetra close of October 23, 2026.

Eli Lilly and Co., US5324571083, Illustration mit AI erstellt.

Eli Lilly (ISIN US5324571083) stock trades at EUR 1,144.30 at Lang & Schwarz on October 26, 2026, 0.03 percent below the Xetra close of October 23, 2026. The company presented first clinical data in platinum-sensitive ovarian cancer on October 24, 2026, adding a pipeline update before its third-quarter results.

Cancer data precede results

Eli Lilly and Company listed the ovarian-cancer data among its investor updates dated October 24, 2026. The same investor page also records a manufacturing expansion in Richmond on October 22, 2026, with 10 new U.S. sites added to the build-out since 2020.

The operating baseline is substantial. Eli Lilly reported second-quarter 2026 revenue of USD 22.97 billion, net income of USD 7.10 billion, diluted earnings per share of USD 7.94 and a 30.90 percent net profit margin in the standardized quarterly figures. Revenue was 47.70 percent higher than in the second quarter of 2025, according to MarketBeat.

Three dates frame the next step

The recent chronology is clear: on October 15, 2026, Lilly set its third-quarter results for October 29, 2026; on October 22, 2026, it cited 10 new U.S. manufacturing sites since 2020; and on October 24, 2026, it presented ovarian-cancer clinical data for ESMO 2026. The figures connect near-term reporting with longer-term pipeline and capacity investment.

What does the target imply?

Goldman Sachs raised its 12-month target from USD 1,371 to USD 1,413 in a note dated October 23, 2026, while keeping a Buy rating, as reported by The Sun Herald. The target is 23.47 percent above the Lang & Schwarz price when measured in separate currencies only as a stated analyst view, so it is not combined with the euro quotation. A counterweight came from Erste Group Bank, which cut its fiscal-year 2026 earnings-per-share estimate to USD 33.87 from USD 36.55 on October 21, 2026, according to MarketBeat.

Dates ahead of the report

The next substantiated date is October 29, 2026, for Lilly's third-quarter 2026 results and conference call at 10:00 a.m. Eastern time, followed by Lilly Innovation Day on December 7, 2026. The company confirmed both dates on its investor-relations page and in its October 15 release.

Stock stays below the yearly high

Eli Lilly stock is 2.68 percent below the EUR 1,175.80 52-week high and above the EUR 697.70 low, using the same euro quotation context as of October 26, 2026. The company's market capitalization is EUR 1,077.5 billion, while the NYSE stock closed at USD 1,273.46 on October 23, 2026.

Eli Lilly stock was trading at EUR 1,144.30 at Lang & Schwarz on October 26, 2026, at 11:30 a.m. CET, minus 0.03 percent versus the Xetra close of October 23, 2026 at EUR 1,144.60. The further course of trading is shown by the continuously updated real-time quote of Eli Lilly stock.